Status:
COMPLETED
Prospective Observational Study to Evaluate a Possible Change in APS Antibody Profiles After COVID-19 Infection or Vaccination
Lead Sponsor:
Cardioangiologisches Centrum Bethanien
Conditions:
Antiphospholipid Syndrome
COVID-19 Infection
Eligibility:
All Genders
18+ years
Brief Summary
Prospective observational study to evaluate a possible change in APS antibody profiles after COVID-19 infection or vaccination
Detailed Description
Prospective observational study to evaluate a possible change in antiphospholipid antibody profiles after coronavirus disease 2019 (COVID-19) infection or vaccination. Patients with antiphospholipid ...
Eligibility Criteria
Inclusion
- Minimum age of 18 years
- Confirmed antiphospholipid syndrome with thromboembolic clinical manifestations (venous thromboembolism, pulmonary embolism, thrombophlebitis etc.)
- Patients with APS antibody risk profile (single/double/triple positivity)
- Written consent for participation in the prospective APSantiCo observational study
Exclusion
- APS with isolated pregnancy complications
- No anticoagulation medication
- Inadequately diagnosed APS
- Non-compliance on the part of the patient
Key Trial Info
Start Date :
March 15 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 24 2022
Estimated Enrollment :
82 Patients enrolled
Trial Details
Trial ID
NCT05313048
Start Date
March 15 2022
End Date
October 24 2022
Last Update
December 21 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cardioangiology Center Bethanien (CCB)
Frankfurt am Main, Germany, 60389